[go: up one dir, main page]

MX2013000242A - Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral. - Google Patents

Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.

Info

Publication number
MX2013000242A
MX2013000242A MX2013000242A MX2013000242A MX2013000242A MX 2013000242 A MX2013000242 A MX 2013000242A MX 2013000242 A MX2013000242 A MX 2013000242A MX 2013000242 A MX2013000242 A MX 2013000242A MX 2013000242 A MX2013000242 A MX 2013000242A
Authority
MX
Mexico
Prior art keywords
hydroxyclloroquine
hydroxychloroquine
antiviral agent
hepatitis
treatment
Prior art date
Application number
MX2013000242A
Other languages
English (en)
Inventor
Philippe Halfon
Original Assignee
Panmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panmed Ltd filed Critical Panmed Ltd
Publication of MX2013000242A publication Critical patent/MX2013000242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente métodos para tratar una enfermedad relacionada con el virus de hepatitis O (HCV), que comprenden administrar al sujeto una cantidad terapéuticamente efectiva de hidroxicloroquina. Se divulgan cantidades terapéuticamente efectivas de hidroxicloroquina que son suficientes para inhibir la autofagia inducida por HCV en el sujeto. Un agente antiviral se puede co-administrar con la hidroxicloroquina. Se divulgan métodos que utilizan combinaciones sinergísticas de hidroxicloroquina y un agente antiviral. Además se divulgan composiciones que comprenden hidroxicloroquina y un agente antiviral, así como hidroxicloroquina y usos de la misma para el tratamiento de una enfermedad relacionada con el virus de hepatitis O (HCV).
MX2013000242A 2010-06-24 2011-06-23 Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral. MX2013000242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35801410P 2010-06-24 2010-06-24
PCT/IB2011/052762 WO2011161644A1 (en) 2010-06-24 2011-06-23 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent

Publications (1)

Publication Number Publication Date
MX2013000242A true MX2013000242A (es) 2014-04-14

Family

ID=44630083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000242A MX2013000242A (es) 2010-06-24 2011-06-23 Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.

Country Status (10)

Country Link
US (2) US8987302B2 (es)
EP (1) EP2585065A1 (es)
JP (1) JP2013529627A (es)
CN (1) CN103096891A (es)
AU (1) AU2011268498A1 (es)
BR (1) BR112012033022A2 (es)
CA (1) CA2803093A1 (es)
IN (1) IN2012MN02896A (es)
MX (1) MX2013000242A (es)
WO (1) WO2011161644A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103096891A (zh) 2010-06-24 2013-05-08 判米德有限公司 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN103145811B (zh) * 2013-03-15 2014-05-07 深圳翰宇药业股份有限公司 一种合成阿拉泊韦的方法
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CA3175721A1 (en) * 2020-04-20 2021-10-28 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
EP4142773A4 (en) * 2020-04-29 2023-11-01 The Regents Of The University Of Michigan INHIBITION OF VIRAL ENTRY OF SARS-COV-2 BY ADMINISTRATION OF LACTOFERRIN AND ITS USES
JP7477152B2 (ja) 2020-05-12 2024-05-01 国立大学法人 宮崎大学 Ｈｔｌｖ－１関連疾患の発症予防、進展抑制または治療のための剤
JP2024504728A (ja) 2021-01-26 2024-02-01 サイトケアズ （シャンハイ） インコーポレイテッド キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞
CN114796126B (zh) * 2022-04-02 2023-04-18 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) 关节腔注射用硫酸羟氯喹缓释微球及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5314894A (en) 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
ITBO20020416A1 (it) * 2002-06-28 2003-12-29 Valpharma Sa Uso della clorochina, idrossi-clorochina e derivati 4 amino-chinolinici per l'ottenimento di un farmaco per la terapia anti retrovirale atti
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
CA2516642C (en) 2003-02-21 2010-11-23 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
DE602005026294D1 (de) 2004-07-14 2011-03-24 Novartis Ag Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
WO2006109196A2 (en) 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
WO2010101649A2 (en) * 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
BR112012018897A2 (pt) 2010-01-27 2017-10-03 Ab Pharma Ltd Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
CN103096891A (zh) 2010-06-24 2013-05-08 判米德有限公司 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
US8729014B2 (en) 2010-11-01 2014-05-20 Rfs Pharma, Llc Specific HCV NS3 protease inhibitors
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus

Also Published As

Publication number Publication date
AU2011268498A1 (en) 2013-01-31
US20130202556A1 (en) 2013-08-08
IN2012MN02896A (es) 2015-06-12
CA2803093A1 (en) 2011-12-29
US20130121965A1 (en) 2013-05-16
JP2013529627A (ja) 2013-07-22
WO2011161644A1 (en) 2011-12-29
US8987302B2 (en) 2015-03-24
BR112012033022A2 (pt) 2016-12-20
US8575195B2 (en) 2013-11-05
CN103096891A (zh) 2013-05-08
EP2585065A1 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
DOP2014000067A (es) Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv
DOP2014000049A (es) Métodos para el tratamiento de hcv que comprenden al menos dos agentes antivirales de acción directa (daaas) y ribavirina pero no interferón
ECSP14013315A (es) Inhibidores de aplicación viral
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
UY37997A (es) Agentes antivirales contra la hepatitis b
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
NZ702744A (en) D-amino acid compounds for liver disease
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
PH12015502230B1 (en) Novel viral replication inhibitors
MX350282B (es) Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
MX376327B (es) Regimen de glicosidasa para el tratamiento de enfermedades infecciosas.
MX374835B (es) Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
BR112015002979B8 (pt) Forma cristalina, e, composição farmacêutica
AR052639A1 (es) Composicion vacunal contra el virus de la hepatitis c.
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal